Sander Van Deventer

CSO of Porton Advanced, one of the founding partners and currently an Operating Partner at Forbion Capital Partners; Executive VP Research and Product Development of uniQure, a Nasdaq-listed gene therapy company; Professor of Translational Gastroenterology Leiden University Medical Center. In addition to co-founding Forbion, Sander is a professor in Translational Gastroenterology at the University of Leiden and an accomplished scientist: He authored over 400 peer-reviewed scientific papers, organized several large international scientific conferences, and supervised more than 40 PhD students.In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT N.V.) currently uniQure N.V., developing AAV-based gene therapy products and now listed on Nasdaq (QURE), acting subsequently as CSO, CMO and CEO. He has had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera).